Troy Lister - 21 Jun 2024 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Scientific Officer
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Troy Lister
Issuer symbol
VERV
Transactions as of
21 Jun 2024
Net transactions value
$0
Form type
4
Filing time
25 Jun 2024, 17:05:02 UTC
Next filing
10 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +32,000 $0.000000 32,000 21 Jun 2024 Common Stock 32,000 $5.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on June 21, 2024. 25% of the shares underlying the option will vest on June 21, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until June 21, 2028.